A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
HOME > Discussions on Next PMD Act Amendment
Discussions on Next PMD Act Amendment
-
Japan Cabinet Approves Bill to Amend PMD Act
February 13, 2025
-
PMD Act Set for Amendments Covering Issues Unaddressed over Past Decade: MHLW Official
February 4, 2025
-
Draft Bill to Amend PMD Act Up for LDP Review on Jan. 27
January 23, 2025
-
MHLW Preparing to Submit Bill to Amend PMD Act in Mid-February
January 17, 2025
-
MHLW Publishes Panel Report on PMD Act Amendment
January 14, 2025
-
Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
-
Japan to Require Drug Makers to Set Up Legal Post of “Stable Supply Manager”
November 29, 2024
-
Advisory Panel Backs Transfer of GMP Inspection Authority for New Generics to PMDA
November 5, 2024
-
Panel OKs Withdrawal Rule for Conditional Nod, 2-Year Extension for Pediatric Data Protection towards PMD Act Amendment
October 4, 2024
-
MHLW Lays Out Updated Discussion Timeline for PMD Act Amendment
September 13, 2024
-
MHLW Mulls System to Seek Expert Input for Patent Linkage
July 29, 2024
-
Panelists Wary of Proposed Switch of Generic GMP Inspection Authority to PMDA
July 8, 2024
-
Make Onsite GMP Inspections Mandatory for Patented Meds and New Generics: MHLW Proposal
June 10, 2024
-
MHLW Proposes Creating Legal Provision on RWD-Only Drug Submissions
June 10, 2024
-
Japan Eyes Withdrawal Rule for Conditional Approval, More Flexible Nods
June 10, 2024
-
JPA Wary of FPMAJ Pitch to Allow Non-Pharmacists as Drug Production Managers
May 21, 2024
-
Allow Use of OOS Autologous Cell Products via PMD Act Amendment: FIRM
May 21, 2024
-
Pharma Industry Wants “Internationally Harmonized” Rules under PMD Act
May 20, 2024
-
MHLW Panel Sets Topics for PMD Act Amendment; Pediatrics, Drug Loss on Agenda
April 19, 2024
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…